[1]Duffy DL, Box NF, Chen W, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes[J]. Hum Mol Genet, 2004, 13(4):447-461. [2]Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2[J]. Nat Genet, 2005, 37(2):166-170. [3]Tao YX. Functional characterization of novel melanocortin-3 receptor mutations identified from obese subjects[J]. Biochim Biophys Acta, 2007, 1772(10):1167-1174. [4]Tao YX. The melanocortin-4 receptor:physiology pharmacology and pathophysiology[J]. Endocrine Reviews, 2010, 31(4):506-543. [5]Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency[J]. J Clin Invest, 2000, 106(2):271-279. [6]Hinney A, Schmidt A, Nottebom K, et al. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans[J]. Journal of Clinical Endocrinology and Metabolism, 1999, 84(4):1483-1486. [7]Chen W, Kelly MA, Opitz Araya X, et al. Exocrine gland dysfunction in MC5R-deficient mice:evidence for coordinated regulation of exocrine gland function by melanocortin peptides[J]. Cell, 1997, 91(6):789-798. [8]Bernier V, Lagace M, Lonergan M, et al. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059[J]. Molecular Endocrinology, 2004, 18(8):2074-2084. [9]Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus[J]. Journal of the American Society of Nephrology, 2006, 17(1):232-243. [10]Vos TJ, Caracoti A, Che JL, et al. Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-4, 5-dihydro-1H-imidazole(ML00257364), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model[J]. J Med Chem, 2004, 47(7):1602-1604. [11]Fan ZC, Tao YX. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients[J]. J Cell Mol Med, 2009, 13(9B):3268-3282. [12]Wang XH, Wang HM, Zhao BL, et al. Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17[J]. J Mol Endocrinol, 2014, 53(1):1-13. [13]Conn PM, Ulloa Aguirre A, Janovick JA. G protein-coupled receptor trafficking in health and disease:lessons learned to prepare for therapeutic mutant rescue in vivo[J]. Pharmacol Rev, 2007, 59(3):225-250. [14]Meimaridou E, Gooljar SB, Ramnarace N, et al. The Cytosolic chaperone Hsc70 promotes traffic to the cell surface of intracellular retained melanocortin-4 receptor mutants[J]. Molecular Endocrinology, 2011, 25(9):1650-1660. [15]Conn PM, Ulloa-Aguirre A. Trafficking of G-protein-coupled receptors to the plasma membrane:insights for pharmacoperone drugs[J]. Trends Endocrinol Met, 2010, 21(3):190-197. [16]Granell S, Serra-Juhé C, Martos-Moreno Gá, et al. A novel melanocortin-4 receptor mutation MC4R-P272L associated with severe obesity has increased propensity to be ubiquitinated in the ER in the face of correct folding[J]. PLoS One, 2012, 7(12):e50894. [17]Castro-Fernandez C, Maya-Nunez G, Conn PM. Beyond the signal sequence:protein routing in health and disease[J]. Endocr Rev, 2005, 26(4):479-503. [18]Breit A, Wolff K, Kalwa H, et al. The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and -4 receptors[J]. J Biol Chem, 2006, 281(49):37447-37456.
|